Results 151 to 160 of about 1,143 (221)

Abstracts

Molecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Targeting RANKL Prevents Bone Loss, Improves Muscle Function and Extends Lifespan in Progeroid Mice

Aging Cell, Volume 25, Issue 8, August 2026.
Targeting of RANKL by genetic and pharmacological approaches ameliorates key features of the progeroid phenotype in Zmpste24−/− mice. RANKL intervention restores bone mass, improves muscle phenotype, and extends survival. These findings support further exploration of RANKL‐targeted therapies for Hutchinson‐Gilford progeria syndrome.
Sandra Freitas‐Rodríguez, Alejandra Valle‐Cao, Francisco Rodríguez, Manuel Fernández‐Sanjurjo, Benjamín Fernández‐García, Vanessa Loredo, María Teresa Fernández‐García, Carmen Fiuza‐Luces, Alejandro Lucia, Carlos López‐Otín, Alejandro López‐Soto, Alicia R. Folgueras   +11 more
wiley   +1 more source

A contemporary analysis of the Australian clinical and genetic landscape of spinal muscular atrophy: a registry based study. [PDF]

Lancet Reg Health West Pac
Balaji L, Forbes R, Cairns A, Sampaio H, Kornberg AJ, Sanders L, Lamont P, Liang C, Jones KJ, Nowak K, O'Gorman C, Woodcock I, Briggs N, Yiu EM, Farrar MA, Kariyawasam D.   +15 more
europepmc   +1 more source

The Swedish National Pediatric Cataract Register (PECARE): Coexisting systemic disorders 2007–2023

Acta Ophthalmologica, Volume 104, Issue 5, Page 510-516, August 2026.
Abstract Purpose To analyse the frequency and type of coexisting systemic disorders in children operated on for cataract in Sweden. Methods Data were retrieved from the Swedish National Pediatric Cataract Register (PECARE) for children operated between January 1, 2007, and December 31, 2023 (n = 975), including follow‐ups at age 1, 2, 5 and 10 ...
David Wackerberg, Jenny Gyllén, Birgitte Haargaard, Alf Nyström, Arzu Karatepe Hashas, Anna Linnarsson Wiklund, Eric Trocmé, Ulrika Kjellström, Kristina Tornqvist, Gunilla Magnusson   +9 more
wiley   +1 more source

Single-dose GC101 gene therapy for spinal muscular atrophy types II and III: an open-label single-arm study. [PDF]

World J Pediatr
Ma XW, Jiang XY, Li ZQ, Dong XY, Ma WH, Wang YX, Yu SQ, Gu RJ, Wang XD, Zhong BM, He F, Xu J, Mao YY, Zhang YP, Zhang S, Li T, Li CY, Zhang S, Yang X, Zhu LN, Wu ZJ, Zhou B, Zhuang L, Li QP, Wu XB, Feng ZC.   +25 more
europepmc   +1 more source

Cerebrospinal fluid metabolomics reveals predictive biomarkers of nusinersen therapy efficacy in type II and type III spinal muscular atrophy patients. [PDF]

Neurol Sci
Li D, Sun N, Wu H, Wang X, Shi Y, Yang L, Huang S, Zhang K, Yang C.   +8 more
europepmc   +1 more source

Nationwide Epidemiology of Motor Neuron Diseases in Latvia (2020–2024): Incidence, Prevalence, and Clinical Characteristics

European Journal of Neurology, Volume 33, Issue 8, August 2026.
This first nationwide study of motor neuron diseases (MNDs) in Latvia provides epidemiological and clinical data about 181 patients identified with motor neuron diseases during a 5‐year observational period revealing lower incidence and prevalence rates compared to other European countries.
Vladimirs Krutovs, Arta Grosmane, Renāte‐Ruta Kažmere, Marija Roddate, Gundega Ķauķe, Diāna‐Patrīcija Grosa, Signe Šetlere, Mikus Dīriks, Guntis Karelis, Viktorija Ķēniņa   +9 more
wiley   +1 more source

A perioperative nursing care protocol for patients with spinal muscular atrophy (SMA) type II or type III undergoing spinal surgery: a 4-year experience in 24 patients. [PDF]

Orphanet J Rare Dis
Li G, Xu K, Liu D, Wu N, Zhang TJ, Chen Y.   +5 more
europepmc   +1 more source

Sensory dysfunction in SMA type 2 and 3 - adaptive mechanism or concomitant target of damage? [PDF]

Orphanet J Rare Dis
Koszewicz M, Ubysz J, Dziadkowiak E, Wieczorek M, Budrewicz S.   +4 more
europepmc   +1 more source

Real-world evidence on nusinersen treatment of persons with SMA: a focused review. [PDF]

J Neuromuscul Dis
Matesanz SE, Finkel RS.
europepmc   +1 more source